Royalty Pharma plc RPRX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -49.10% | -44.42% | 23.12% | 2.88% | -47.75% |
| Total Depreciation and Amortization | -4.39% | -6.16% | -- | -- | -- |
| Total Amortization of Deferred Charges | 5.43% | -3.00% | 45.24% | 42.14% | 46.67% |
| Total Other Non-Cash Items | 32.07% | 55.93% | -1.61% | -20.15% | 31.75% |
| Change in Net Operating Assets | -1.54% | 16.15% | 9.14% | 16.36% | 7.58% |
| Cash from Operations | -2.35% | 100.14% | 20.49% | 11.40% | -0.14% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 70.18% | 3.39% | -194.83% | -67.69% | 19.67% |
| Cash from Investing | 70.19% | 26.37% | -194.83% | -67.69% | 19.65% |
| Total Debt Issued | -98.45% | -- | -- | -- | -- |
| Total Debt Repaid | 81.10% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 41.06% | 84.69% | 92.93% | -53.09% | -50.95% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -10.29% | -12.52% | -9.58% | -0.73% | -1.33% |
| Other Financing Activities | 15.11% | -0.48% | 13.91% | -11.65% | -11.56% |
| Cash from Financing | -224.17% | 46.21% | 71.03% | -16.14% | 272.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -197.16% | 149.49% | -120.35% | -1,423.10% | 137.69% |